연구성과로 돌아가기
2024 연구성과별 연구자 정보 (758 / 2344)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Heo, Jeong | Heo, J | 8 | Pusan Natl Univ, Coll Med, Dept Internal Med, Pusan, South Korea | MHQ-1390-2025 | Heo, Jeong | ||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Heo, Jeong | Heo, J | 8 | Pusan Natl Univ Hosp, Biomed Res Inst, Pusan, South Korea | MHQ-1390-2025 | Heo, Jeong | ||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Mai, Ahn | Mai, A | 9 | Nhan Dan Gia Dinh Hosp, Gen Surg Dept, Ho Chi Minh City, Vietnam | ||||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Escobar, Jose | Escobar, J | 10 | Hosp San Lucas Cardiol Sureste, Chiapas, Mexico | ||||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Lopez Chuken, Yamil Alonso | Chuken, YAL | 11 | I Can Oncol Ctr, New Leon, Mexico | ||||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Yoon, Jung-Hwan | Yoon, JH | 12 | Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea | ||||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Yoon, Jung-Hwan | Yoon, JH | 12 | Seoul Natl Univ, Liver Res Inst, Coll Med, Seoul, South Korea | ||||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Tak, Won Young | Tak, WY | 13 | Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea | ||||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Suttichaimongkol, Tanita | Suttichaimongkol, T | 14 | Khon Kaen Univ, Fac Med, Dept Med, Div Gastroenterol & Hepatol, Khon Kaen, Thailand | JDW-6886-2023 | Suttichaimongkol, Tanita | ||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Bouattour, Mohamed | Bouattour, M | 15 | Hop Beaujon, AP HP, Med Oncol, Paris, France | ||||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Lin, Shi-Ming | Lin, SM | 16 | Chang Gung Mem Hosp, Linkou Med Ctr, Dept Internal Med, Taoyuan, Taiwan | NPI-5122-2025 | Lin, Shiming | ||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Zotkiewicz, Magdalena | Zotkiewicz, M | 17 | AstraZeneca, Oncol Biometr, Late Oncol Stat, Warsaw, Poland | ||||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Udoye, Stephanie | Udoye, S | 18 | AstraZeneca, Global Med Dev, Gaithersburg, MD USA | ||||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Cohen, Gordon | Cohen, G | 19 | AstraZeneca, Global Med Dev, Gaithersburg, MD USA | ||||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Sangro, Bruno | Sangro, B | 20 | Clin Univ Navarra, Liver Unit, Pamplona, Spain | AFW-4106-2022 | Sangro, Bruno |
페이지 이동: